Targeting Lung Cancer Stem Cells: Research and Clinical Impacts

Frontiers in Oncology

Juntang Lin¹  Nazilah Abdul Satar³  Siti Hawa Ngalim³  Badrul Hisham Yahaya³  Noor Hanis Abu Halim³  Narazah Mohd Yusoff³  Norashikin Zakaria³ 

[1] College of Biomedical Engineering, Xinxiang Medical University (XXMU), Xinxiang, China;College of Life Science and Technology, Xinxiang Medical University (XXMU), Xinxiang, China;Regenerative Medicine Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, Kepala Batas, Penang, Malaysia;

关键词: lung cancer;    non-small cell lung cancer;    cancer stem cells;    neoplastic stem cells;    surface markers;    therapeutics;   

DOI  :  10.3389/fonc.2017.00080

来源: DOAJ

【 摘 要 】

Lung cancer is the most common cancer worldwide, accounting for 1.8 million new cases and 1.6 million deaths in 2012. Non-small cell lung cancer (NSCLC), which is one of two types of lung cancer, accounts for 85–90% of all lung cancers. Despite advances in therapy, lung cancer still remains a leading cause of death. Cancer relapse and dissemination after treatment indicates the existence of a niche of cancer cells that are not fully eradicated by current therapies. These chemoresistant populations of cancer cells are called cancer stem cells (CSCs) because they possess the self-renewal and differentiation capabilities similar to those of normal stem cells. Targeting the niche of CSCs in combination with chemotherapy might provide a promising strategy to eradicate these cells. Thus, understanding the characteristics of CSCs has become a focus of studies of NSCLC therapies.

【 授权许可】

Unknown